Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint

Endocrine Reviews

Volumn 23, Issue 1, 2002, Pages 16-37

  Marcus, Robert ^a,c   Wong, Mayme ^b   Heath III, Hunter ^b   Stock, John L ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ETIDRONIC ACID; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MESTRANOL; PHYTOESTROGEN; PLACEBO; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TIBOLONE; VITAMIN D; VITAMIN D DERIVATIVE;

ADULT; AGE; AGED; BONE DENSITY; BONE MINERAL; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESTROGEN THERAPY; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; METHODOLOGY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; POPULATION RESEARCH; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; STATISTICAL ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0036185685     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.23.1.0453     Document Type: Review

References (151)

1. Involutional osteoporosis
2. The prevention and treatment of osteoporosis
3. Postmenopausal osteoporosis
4. Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines
5. Treatment of postmenopausal osteoporosis
6. A review of clinical trials of therapies for osteoporosis using fracture as an end point
7. Users' guides to the medical literature. VI. How to use an overview
8. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
9. Effects of body size and skeletal site on the estimated prevalence of osteoporosis in women and men
10. The association of radiographically detected vertebral fractures with back pain and function: A prospective study
11. Contribution of vertebral deformities to chronic back pain and disability. The study of Osteoporotic Fractures Research Group
12. Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group
13. Vertebral fracture and other predictors of physical impairment and health care utilization
14. Consequences of vertebral deformities in older men and women
15. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures
16. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group
17. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass
18. Defining incident vertebral deformity: A prospective comparison of several approaches. The study of Osteoporotic Fractures Research Group
19. The burden of osteoporosis
20. The worldwide problem of osteoporosis: Insights afforded by epidemiology
21. How should the risk of fracture in postmenopausal women be assessed?
22. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
23. Long-term fracture prediction by bone mineral assessed at different skeletal sites
24. Interim report and recommendations of the World Health Organization Task-Force for osteoporosis
25. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
26. Osteoporosis: Trials and tribulations
27. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs
28. What proportion of the effects of raloxifene (RLX) on vertebral fracture risk can be directly attributed to its bone mineral density (BMD) effects?
29. Relationships between changes in bone mineral density and the risk of new vertebral fractures with raloxifene treatment
30. How much of the reduction in risk of vertebral fractures by alendronate is explained by increased spine BMD?
31. Predicting the effect of antiresorptive treatments on risk of vertebral fractures: A meta-analysis
32. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
33. Antifracture efficacy of antiresorptive agents are related to changes in bone density
34. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel
35. Clinical use of biochemical markers of bone remodeling: Current status and future directions
36. Bone mass, bone fragility, and the decision to treat
37. Post hoc subgroup analysis and the truth of a clinical trial
38. Correcting calcium nutritional deficiency prevents spine fractures in elderly women
39. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients
40. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
41. Bone status and fracture rates in two regions of Yugoslavia
42. Dietary calcium and risk of hip fracture: 14-Year prospective population study
43. Calcium for prevention of osteoporotic fractures in postmenopausal women
44. 3 and calcium to prevent hip fractures in the elderly women
45. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
46. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
47. Vitamin D supplementation and fracture incidence in elderly persons: A randomized, placebo-controlled clinical trial
48. Annual injection of vitamin D and fractures of aged bones
49. Hormone replacement therapy, heart disease, and other considerations
50. The lack of effect of progestogen on bone
51. Treatment of postmenopausal osteoporosis with transdermal estrogen
52. What is a vertebral fracture?
53. Events per person year - A dubious concept
54. Prevention of spinal osteoporosis in oophorectomised women
55. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
56. Effect of risedronate on the risk of hip fracture in elderly women
57. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial
58. Estrogen replacement therapy I: A 10-year prospective study in the relationship to osteoporosis
59. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group
60. Design of the Women's Health Initiative clinical trial and observational study
61. Selective estrogen receptor modulators: A look ahead
62. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
63. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis
64. Raloxifene 60 mg/day has effects within 12 months in postmenopausal osteoporosis treatment and prevention studies
65. Bisphosphonates: Mechanisms of action
66. The pharmacology and therapeutic utility of bisphosphonates
67. Etidronate therapy in the treatment and prevention of osteoporosis
68. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
69. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
70. Updated data on proximal femur bone mineral levels of US adults
71. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
72. The early antifracture efficacy of alendronate in women with osteoporosis: Results from FIT
73. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention trial
74. Prevention of nonvertebral fractures by alendronate: A meta-analysis
75. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
76. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
77. Effect of calcitonin on vertebral and other fractures
78. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
79. What PROOF proves about calcitonin and clinical trials
80. A tale of two worlds in prescribing etidronate for osteoporosis
81. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
82. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
83. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
84. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: Results of three years of treatment
85. Cyclic etidronate: Has the rose lost its bloom?
86. Livial: A review of clinical studies
87. Treatment of postmenopausal osteoporosis with calcitriol or calcium
88. Osteoporosis and its treatment
89. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol: A randomized controlled study
90. Postmenopausal osteoporosis: No effect of three years treatment with 1,25-dihydroxycholecalciferol
91. Calcitriol in the treatment of postmenopausal osteoporosis
92. Calcitriol treatment is not effective in postmenopausal osteoporosis
93. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis
94. 3
95. Clinical review 97: Potential health benefits of dietary phytoestrogens: A review of the clinical, epidemiological, and mechanistic evidence
96. Hip fracture rates in Hong Kong and the United States, 1988 through 1989
97. Ipriflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women
98. The role of isoflavones in menopausal health: Consensus opinion of The North American Menopause Society
99. Prevention and treatment of osteoporosis: Efficacy of combination of hormone replacement therapy with other antiresorptive agents
100. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
101. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
102. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
103. Effects of raloxifene (RLX), alendronate (ALN), and RLX + ALN on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal women with osteoporosis
104. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study
105. Predicting bone loss and fracture risk with biochemical markers: A review
106. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib
107. Bone microdamage and skeletal fragility in osteoporotic and stress fractures
108. How long should patients with osteoporosis be treated with bisphosphonates?
109. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions trial
110. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
111. Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women
112. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative study
113. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
114. Venous thromboembolic events associated with hormone replacement therapy
115. Hormone replacement therapy: Where are we now?
116. Compliance with hormone replacement therapy: Are women receiving the full impact of hormone replacement therapy preventative health benefits?
117. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
118. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
119. Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene
120. The effect of raloxifene on risk of breast cancer in postmenopausal women
121. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Multiple outcomes of raloxifene evaluation
122. Effect of SERMs on breast tissue
123. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation
124. Esophagitis associated with the use of alendronate
125. Upper gastrointestinal tract safety profile of alendronate: The Fracture Intervention trial
126. Risedronate reduces fracture risk in women with established postmenopausal osteoporosis
127. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures
128. Osteoporosis prevention, diagnosis, and therapy
129. Epidemiology of spinal osteoporosis
130. Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group
131. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women
132. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density
133. Bone matters: Are density increases necessary to reduce fracture risk?
134. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean
135. Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study
136. Effects of long-term estrogen replacement therapy. I. Metabolic effects
137. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
138. Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women
139. Menopausal estrogen therapy and hip fractures
140. The risk of hip fracture in postmenopausal females with or without estrogen drug exposure
141. An epidemiologic study of hip fracture in postmenopausal women
142. Long-term estrogen replacement therapy prevents bone loss and fractures
143. Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence
144. Hip fracture and the use of estrogens in postmenopausal women. The Framingham study
145. Hormone replacement therapy and the risk for first hip fracture: A prospective, population-based cohort study
146. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women
147. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture
148. Risks of perimenopausal fractures - A prospective population-based study
149. Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture
150. Hormone replacement therapy and risk of hip fracture: Population based case-control study
151. A five year prospective study of BMD and fracture risk in HRT treated and untreated perimenopausal women